Takeda’s Andy Plump Tells The Japanese Pharma’s New Story

R&D President Discusses ‘Wave 1’ Drugs, Deal-Making Priorities

As Takeda pays down debt associated with the acquisition of Shire and advances R&D programs toward global filings, the company is selling its growth plan to investors – but are they buying?

Small light bulb glowing on the desk, with notebook
Takeda is telling an updated growth story after its Shire acquisition • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd. has reshaped its image as a growing global company, which has led to success in recruiting top talent and negotiating agreements with new partners, according to president of research and development Andy Plump. But despite writing a new growth story, the Japanese big pharma still is struggling to sell its plan to investors.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

More from Business